5 ms·
I can't believe they've received three quarters of a billion dollars of investment.
by dekhn 7y ago
I can't believe they've received three quarters of a billion dollars of investment.
- jw887c 7y agoIts not surprising when you realize how bad wealth inequality has made investors searching desperately for any place to put money.
- redis_mlc 7y ago"Anne Wojcicki married Google co-founder Sergey Brin in May 2007." There ya go. 23andMe was a vanity project for Sergey's wife (now ex-wife.) https://en.wikipedia.org/wiki/Anne_Wojcicki https://en.wikipedia.org/wiki/Anne_Wojcicki Same story for Marissa Mayer.
- dekhn 7y agoI know quite well (have met all the people involved), but I still can't believe how much money has been sunk into them.
- downerending 7y agoOne of the joys of being rich is being able to spend your money however you like. It's a caution to the rest of us, though. My annual salary is just a rounding error to them, and it's not worth their time to consider my individual fate in any way.
- dehrmann 7y agoImportantly, Alphabet is an inventor in 23andme. Her sister is also the head of YouTube. This still isn’t as bad as Elon Musk using Tesla to bail out his cousin’s failing Solar City.
- wahern 7y agoThe largest chunk, $300 million, was a buy-in from GlaxoSmithKline, with which it purchased access to the database and research. Given the slowing pace of drug development, that was probably a very good "investment" by GSK. But maybe it was a bad one for 23andMe if it limits the scope of deals they can do with other pharmaceutical companies.
- dekhn 7y agoIt remains unclear that 23&Me's data will truly be transformative in drug development (this has been a criticism of the human genome project since it finished and most predictions for human health still haven't panned out). There's a lot of narrative and noise there, but not a lot of useful activity (yes, I know 23&Me is touting one drug at this point).
- wahern 7y agoOn the last big 23andMe thread at least one researcher commented that their data has been immensely useful. And I'm fairly certain I've read a few similar comments on HN before then. A researcher friend of mine made fun of me for signing up to 23andMe when they first offered their test. SNPs, he told me, didn't tell you much of substance. To which I replied, haven't the last 20 years (almost 30, now) of genetic research been built almost entirely on SNP-based studies? He didn't have a comeback for that--he was in the middle of his Ph.D at the time. A few years later he signed up for 23andMe =) It's true: we're so incredibly far from the type of personalized medicine that genetic researchers promised. I'm not sure what "transformative" would look like, but I don't think 23andMe's valuation exceeds its potential, if only because of the number of 0's in medical expenditures, globally but especially in the U.S.
- dekhn 7y agoResearchers talk a big game, but genomics has turned out to be a massive disappointment and really oversold. SNP analysis is useful, but leaves out a lot of important variation. Also, it's taken the field a long time to understand that most interesting phenotypes are complex nonlinear functions of many different variations, which makes health discovery far more challenging.
- wahern 7y ago> SNP analysis is useful, but leaves out a lot of important variation That's true of everything in medicine, especially without SNP analysis. And it'll remain true even with whole genome sequencing. I think the biggest problem is that until now medicine has revolved around the study and treatment cohorts. Even once we identify the variations, we still need to develop particularized treatments. It requires a tremendous shift in how medicine has been practiced. I think that's what 23andMe was hoping to bootstrap, and why they're not shy about sharing their database with researchers. Moving from traditional medicine to individual treatment will be done incrementally--splitting what was once a monolithic group into ever smaller subgroups until, eventually, centuries from now, everyone receives tailored treatment. SNPs can still be useful because we're still transitioning from treating monolithic groups, so the variations missed by SNPs are details that we would be unable to leverage, anyhow. The state-of-the-art is always light years ahead of what we can manage to operationalize at scale. Isn't this the lesson so many startups have to learn? On the ground, the real value add always comes in figuring out to make some new technique useful and profitable, and for various reasons it's usually the case that the techniques are already ancient by the time they see substantial use in the market.